Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01077)
Name
Finafloxacin
Synonyms    Click to Show/Hide the Synonyms of This API
Finafloxacin; 209342-40-5; Xtoro; UNII-D26OSN9Q4R; D26OSN9Q4R; CHEBI:85176; 209342-40-5 (free base); Finafloxacin (INN); Finafloxacin [INN]; 8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; AL-60371; 8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; gastrochinolon; gastroquinolone; 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Xtoro (TN); BAY35-3377; QCR-30; SCHEMBL1002869; CHEMBL1908370; GTPL10809; DTXSID10175096; BCP23882; ZINC3985346; AL60371; CS-5557; DB09047; SB17124; NCGC00510315-02; (-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1; AC-29291; HY-13451; D10575; Q21011229; (-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-; 3-Quinolinecarboxylic acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-; 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid; 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid,hydrochloride; 8-cyano-1-cyclopropyl-6-fluoro-7-((1S,6S)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Clinical Status
Approved
PubChem CID
11567473
Formula
C20H19FN4O4
Canonical SMILES
C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
InChI
1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
InChIKey
FYMHQCNFKNMJAV-HOTGVXAUSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11567473"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 398.4 Topological Polar Surface Area 106
XlogP -0.7 Complexity 806
Heavy Atom Count 29 Rotatable Bond Count 3
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 9
Full List of Drug Formulations (DFMs) Containing This API
          Finafloxacin 0.3% suspension Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium Chloride; Hydroxyethylcellulose; Tyloxapol; Magnesium Chloride; Purified Water
                   Dosage Form Suspension
                   Company Merlion Pharms Gmbh

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.